Intec Pharma (NASDAQ:NTEC) Shares Gap Up to $1.25

Shares of Intec Pharma Ltd (NASDAQ:NTEC) gapped up before the market opened on Tuesday . The stock had previously closed at $1.21, but opened at $1.25. Intec Pharma shares last traded at $1.30, with a volume of 8,938,400 shares.

A number of equities analysts recently commented on NTEC shares. LADENBURG THALM/SH SH reaffirmed a “hold” rating on shares of Intec Pharma in a research note on Monday, August 12th. ValuEngine raised shares of Intec Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. HC Wainwright cut shares of Intec Pharma from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 7th. Maxim Group cut shares of Intec Pharma from a “buy” rating to a “hold” rating in a research note on Monday, July 22nd. Finally, Oppenheimer cut shares of Intec Pharma from an “outperform” rating to a “market perform” rating in a research note on Monday, July 22nd. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $12.17.

The business’s fifty day moving average is $0.62 and its two-hundred day moving average is $4.26. The company has a market cap of $37.75 million, a P/E ratio of -0.93 and a beta of -0.03.

In related news, CEO Jeffrey A. Meckler acquired 100,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was bought at an average price of $0.46 per share, for a total transaction of $46,000.00. Following the acquisition, the chief executive officer now directly owns 176,761 shares of the company’s stock, valued at approximately $81,310.06. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have purchased a total of 145,000 shares of company stock valued at $71,350 in the last quarter. 3.30% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall Wace North America L.P. bought a new stake in Intec Pharma during the 1st quarter valued at about $117,000. JPMorgan Chase & Co. bought a new stake in Intec Pharma during the 2nd quarter valued at about $125,000. Delek Group Ltd. bought a new stake in Intec Pharma during the 1st quarter valued at about $154,000. Private Advisors LLC bought a new stake in Intec Pharma during the 1st quarter valued at about $225,000. Finally, Morgan Stanley lifted its holdings in Intec Pharma by 38.4% during the 2nd quarter. Morgan Stanley now owns 81,931 shares of the biotechnology company’s stock valued at $356,000 after buying an additional 22,715 shares in the last quarter. Institutional investors own 35.51% of the company’s stock.

Intec Pharma Company Profile (NASDAQ:NTEC)

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

Recommended Story: How is a price target determined?

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.